| Geld/Brief | 12,00 € / 12,30 € |
| Spread | +2,50% |
| Schluss Vortag | 12,15 € |
| Gehandelte Stücke | 0 |
| Tagesvolumen Vortag | - |
| Tagestief 12,15 € Tageshoch 12,15 € | |
| 52W-Tief 6,825 € 52W-Hoch 17,35 € | |
| Jahrestief 7,20 € Jahreshoch 12,35 € | |
| Umsatz in Mio. | 119,91 $ |
| Operatives Ergebnis (EBIT) in Mio. | -5,10 $ |
| Jahresüberschuss in Mio. | -56,39 $ |
| Umsatz je Aktie | 8,15 $ |
| Gewinn je Aktie | -3,83 $ |
| Gewinnrendite | -36,62% |
| Umsatzrendite | - |
| Return on Investment | -27,81% |
| Marktkapitalisierung in Mio. | 242,31 $ |
| KGV (Kurs/Gewinn) | -4,30 |
| KBV (Kurs/Buchwert) | 1,57 |
| KUV (Kurs/Umsatz) | 2,02 |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | +75,95% |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Frankfurt | 11,20 € | +24,44% | 9,00 € | 27.02.26 | |
| Stuttgart | 10,90 € | +19,78% | 9,10 € | 27.02.26 | |
| L&S RT | 12,15 € | 0 % | 12,15 € | 16:33 | |
| NYSE | 14,17 $ | +10,49% | 12,825 $ | 27.02.26 | |
| Nasdaq | 14,37 $ | +12,27% | 12,80 $ | 27.02.26 | |
| AMEX | 12,56 $ | +13,77% | 11,04 $ | 26.02.26 | |
| Gettex | 12,10 € | +13,08% | 10,70 € | 27.02.26 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 28.02.26 | 12,15 | - |
| 27.02.26 | 12,15 | - |
| 26.02.26 | 10,85 | - |
| 25.02.26 | 9,275 | - |
| 24.02.26 | 9,225 | - |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 9,025 € | +34,63% |
| 1 Monat | 7,775 € | +56,27% |
| 6 Monate | 8,00 € | +51,88% |
| 1 Jahr | 16,80 € | -27,68% |
| 5 Jahre | 32,00 € | -62,03% |
| Marktkapitalisierung | 118,85 Mio. € |
| Aktienanzahl | 14,65 Mio. |
| Streubesitz | 9,45% |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Pharmazeutika |
| Aktientyp | Stammaktie |
| +14,12% | Trigran Investments Inc |
| +10,60% | BlackRock Inc |
| +9,95% | Caligan Partners LP |
| +5,41% | Vanguard Group Inc |
| +4,32% | Dimensional Fund Advisors, Inc. |
| +4,08% | Opaleye Management Inc |
| +3,67% | BOOTHBAY FUND MANAGEMENT, LLC |
| +3,66% | Renaissance Technologies Corp |
| +3,16% | Alta Fundamental Advisers LLC |
| +2,84% | Capital Management Corp |
| +2,25% | State Street Corp |
| +2,23% | Geode Capital Management, LLC |
| +1,32% | Stonepine Capital Management Llc |
| +0,93% | Millennium Management LLC |
| +0,92% | Charles Schwab Investment Management Inc |
| +0,86% | D. E. Shaw & Co LP |
| +0,84% | Envestnet Asset Management Inc |
| +0,83% | Jacobs Levy Equity Management, Inc. |
| +0,80% | Northern Trust Corp |
| +0,75% | Morgan Stanley - Brokerage Accounts |
| +17,01% | Weitere |
| +9,45% | Streubesitz |
Zahlen für Q3/24
https://ir.anika.com/2024-10-31-Anika-Reports-Third-Quarter-2024-Financial-Results
Die Zahlen sehen nicht gerade berauschend aus.
Zahlen für Q2/23
https://ir.anika.com/2023-08-08-Anika-Reports-Second-Quarter-2023-Financial-Results
Zahlen für Q4/21
"the Company expects its overall revenue for fiscal year 2022 to be up low to mid-single digit percent compared with 2021"
https://ir.anikatherapeutics.com/news-releases/news-release-details/anika-reports-fourth-quarter-and-year-end-2021-financial-results
